{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T09:39:23Z","timestamp":1767001163026,"version":"3.48.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,29]]},"DOI":"10.7759\/cureus.100311","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T09:36:12Z","timestamp":1767000972000},"source":"Crossref","is-referenced-by-count":0,"title":["Oligocentric Castleman Disease (OligoCD): A Novel Diagnostic Entity in the Spectrum of Castleman Disease"],"prefix":"10.7759","author":[{"given":"Ritasman","family":"Baisya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juwain","family":"Nehil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikas","family":"Dagar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukdev","family":"Manna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000931","article-title":"Overview of Castleman disease","volume":"135","author":"Dispenzieri A","year":"2020","unstructured":"Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease. Blood. 2020, 135:1353-64. 10.1182\/blood.2019000931","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-746933","article-title":"International, evidence-based consensus diagnostic criteria for HHV-8-negative\/idiopathic multicentric Castleman disease","volume":"129","author":"Fajgenbaum DC","year":"2017","unstructured":"Fajgenbaum DC, Uldrick TS, Bagg A, et al.. International, evidence-based consensus diagnostic criteria for HHV-8-negative\/idiopathic multicentric Castleman disease. Blood. 2017, 129:1646-57. 10.1182\/blood-2016-10-746933","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100158","article-title":"ACCELERATE: a patient-powered natural history study design enabling clinical and therapeutic discoveries in a rare disorder","volume":"1","author":"Pierson SK","year":"2020","unstructured":"Pierson SK, Khor JS, Ziglar J, et al.. ACCELERATE: a patient-powered natural history study design enabling clinical and therapeutic discoveries in a rare disorder. Cell Rep Med. 2020, 1:100158. 10.1016\/j.xcrm.2020.100158","journal-title":"Cell Rep Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-12797-y","article-title":"Comprehensive analysis of 65 patients with Castleman disease in a single center in China","volume":"12","author":"Wang XQ","year":"2022","unstructured":"Wang XQ, Zhong NN, Sun Q, et al.. Comprehensive analysis of 65 patients with Castleman disease in a single center in China. Sci Rep. 2022, 12:8694. 10.1038\/s41598-022-12797-y","journal-title":"Sci Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11112008","article-title":"Clinical and pathological characteristics of hyaline-vascular type unicentric Castleman disease: a 20-year retrospective analysis","volume":"11","author":"Nishimura MF","year":"2021","unstructured":"Nishimura MF, Nishimura Y, Nishikori A, Maekawa Y, Maehama K, Yoshino T, Sato Y. Clinical and pathological characteristics of hyaline-vascular type unicentric Castleman disease: a 20-year retrospective analysis. Diagnostics (Basel). 2021, 11:2008. 10.3390\/diagnostics11112008","journal-title":"Diagnostics (Basel)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2017.09.002","article-title":"Castleman disease pathogenesis","volume":"32","author":"Fajgenbaum DC","year":"2018","unstructured":"Fajgenbaum DC, Shilling D. Castleman disease pathogenesis. Hematol Oncol Clin North Am. 2018, 32:11-21. 10.1016\/j.hoc.2017.09.002","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014391","article-title":"Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry","volume":"9","author":"Pierson SK","year":"2025","unstructured":"Pierson SK, Brandstadter JD, Torigian DA, et al.. Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry. Blood Adv. 2025, 9:1952-65. 10.1182\/bloodadvances.2024014391","journal-title":"Blood Adv"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/3718305","article-title":"Clinical analysis of Castleman\u2019s disease of the lacrimal gland","volume":"2020","author":"Li D","year":"2020","unstructured":"Li D, Tang D, Sun F. Clinical analysis of Castleman\u2019s disease of the lacrimal gland. J Ophthalmol. 2020, 2020:3718305. 10.1155\/2020\/3718305","journal-title":"J Ophthalmol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-024-03775-1","article-title":"Plasma cell type Castleman's disease of lacrimal gland: a case report and literature review","volume":"24","author":"Xu L","year":"2024","unstructured":"Xu L, Li J, Xu X, Ren T, Ma J. Plasma cell type Castleman's disease of lacrimal gland: a case report and literature review. BMC Ophthalmol. 2024, 24:508. 10.1186\/s12886-024-03775-1","journal-title":"BMC Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.05.002","article-title":"Excellent outcomes with surgery or radiotherapy in the management of Castleman disease including a case of oligocentric disease","volume":"20","author":"Beckham TH","year":"2020","unstructured":"Beckham TH, Yang JC, Chau KW, Noy A, Yahalom J. Excellent outcomes with surgery or radiotherapy in the management of Castleman disease including a case of oligocentric disease. Clin Lymphoma Myeloma Leuk. 2020, 20:685-9. 10.1016\/j.clml.2020.05.002","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4602","article-title":"Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease","volume":"106","author":"Nishimoto N","year":"2005","unstructured":"Nishimoto N, Kanakura Y, Aozasa K, et al.. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005, 106:2627-32. 10.1182\/blood-2004-12-4602","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S60514","article-title":"Update and new approaches in the treatment of Castleman disease","volume":"7","author":"Chan KL","year":"2016","unstructured":"Chan KL, Lade S, Prince HM, Harrison SJ. Update and new approaches in the treatment of Castleman disease. J Blood Med. 2016, 7:145-58. 10.2147\/JBM.S60514","journal-title":"J Blood Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15019","article-title":"The full spectrum of Castleman disease: 273 patients studied over 20\u00a0years","volume":"180","author":"Oksenhendler E","year":"2018","unstructured":"Oksenhendler E, Boutboul D, Fajgenbaum D, et al.. The full spectrum of Castleman disease: 273 patients studied over 20\u00a0years. Br J Haematol. 2018, 180:206-16. 10.1111\/bjh.15019","journal-title":"Br J Haematol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010801)92:3<670::aid-cncr1369>3.0.co;2-q","article-title":"Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy","volume":"92","author":"Chronowski GM","year":"2001","unstructured":"Chronowski GM, Ha CS, Wilder RB, Cabanillas F, Manning J, Cox JD. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer. 2001, 92:670-6. 10.1002\/1097-0142(20010801)92:3&lt;670::aid-cncr1369&gt;3.0.co;2-q","journal-title":"Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)00006-5","article-title":"Idiopathic multicentric Castleman\u2019s disease: a systematic literature review","volume":"3","author":"Liu AY","year":"2016","unstructured":"Liu AY, Nabel CS, Finkelman BS, et al.. Idiopathic multicentric Castleman\u2019s disease: a systematic literature review. Lancet Haematol. 2016, 3:E163-75. 10.1016\/S2352-3026(16)00006-5","journal-title":"Lancet Haematol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/440574-oligocentric-castleman-disease-oligocd-a-novel-diagnostic-entity-in-the-spectrum-of-castleman-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T09:36:12Z","timestamp":1767000972000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/440574-oligocentric-castleman-disease-oligocd-a-novel-diagnostic-entity-in-the-spectrum-of-castleman-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.100311","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,29]]}}}